SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988; 123: 26002.
  • 2
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 30919.
  • 3
    Bucay N, Sarosi I, Dunston CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 12608.
  • 4
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differnetiation and activation. Cell 1998; 93: 16576.
  • 5
    Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone 1999; 25: 51723.
  • 6
    Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 2000; 157: 43548.
  • 7
    Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, et al. The ligand for osteoprotegerin directly activates mature osteoclasts. J Cell Biol 1999; 145: 52738.
  • 8
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymph node development and lymph node organogenesis. Nature 1999; 397: 31523.
  • 9
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 3049.
  • 10
    Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNF alpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNF alpha-mediated inflammatory arthritis. J Bone Miner Res 2004; 19: 20713.
  • 11
    Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 2508.
  • 12
    Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A, et al. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid: a comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005; 26: 639. Epub 2005 May 12.
  • 13
    Anderson DM, Maraaskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T cell growth and dendritic cell function. Nature 1997; 390: 1759.
  • 14
    Doran P, Russell SJ, Chen D, Greiner SM, Ludvigson J, Khosla S, et al. Gene transfer of osteoprotegerin-Fc inhibits osteolysis and disease progression in a murine model of multiple myeloma [abstract]. J Bone Miner Res 2002; 17; S147.
  • 15
    Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146: 323543.
  • 16
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 17
    Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, et al. Sustained antiresorptive effects after a single treatment with human econbinant osteoprotegerin: a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003; 18: 8528.
  • 18
    Kostenuik PJ, Capparelli C, Morony S, Morony S, Adamu S, Shimamoto G, et al. OPG and PTH(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001; 142: 4295304.
  • 19
    Doran PM, Turner RT, Chen D, Facteau SM, Ludvigson JM, Khosla S, et al. Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 2004; 32: 3519.
  • 20
    Bolon B, Shalhoub V, Kostenuik PJ, Campagnulol G, Morony S, Boyle WJ, et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum 2002; 46: 312135.
  • 21
    Morony S, Lu J, Capparelli C, Dunstan CR, Lacey DL, Kostenuik PJ. Osteoprotegerin prevents bone loss in a rat model of glucocorticoid induced osteoporosis [abstract]. J Bone Miner Res 2001; 16 Suppl 1: S148.
  • 22
    Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001: 16: 34860.
  • 23
    Cohen S, McClung M, Lewiecki EM, Bolognese MA, Woodson G, Moffett A, et al. AMG 162 administered every 6 months causes rapid and sustained decreases in bone turnover in postmenopausal women with low bone mineral density (BMD). Arthritis Rheum 2004; 50 Suppl 9: s438
  • 24
    McClung MR, Lewiecki EM, Bolognese MA, Woodson G, Moffett A, Peacock M, et al. AMG 162 increases bone mineral density (BMD) within 1 month in postmenopausal women with low BMD [abstract]. J Bone Miner Res 2004; 19 Suppl 1: S20.